Hybrid Telehealth Medical Retina Clinic Due to Provider Exposure and Quarantine During COVID-19 Pandemic

Figures & data

Table 1 Demographic Features

Gender
Male	194 (49.3%)
Female	200 (50.7%)
Total Patients	394
Age (years)
Mean ± SD (Range)	70.96 ± 14.4 (28–95)
Disease
AMD	199 (50.5%)
DME	84 (21.3%)
RVO	69 (17.5%)
Others	42 (10.7%)
Laterality of injections
RE Injections only	125 patients (31.7%)
LE Injections only	140 patients (35.5%)
IBE injections	129 patients (32.8%)
Total injections	523 injections

Abbreviations: AMD, age macular degeneration; DME, diabetic macular edema; RVO, retinal vein occlusion with cystoid macular edema, Others (e.g. myopic choroidal neovascularization, polypoidal choroidal vasculopathy, punctate inner choroidopathy); RE, right eye; LE, left eye; IBE, in both eyes.

Table 2 Clinical Features

Mean Visual Acuity (LogMAR) ± SD (Range)	nAMD	DME	RVO	Others	Total
	0.67±0.65 (0–5)	0.5±0.5 (0–3)	0.47±0.5 (0–2)	0.6±0.65 (0–3)	0.6±0.6 (0–5)
Treatment Protocol
Monthly injections	221 (56.10%)
Treat-and-Extend	173 (43.90%)
Central Sub-field Thickness (CST)
Mean ± SD (Range)			318.13 ± 107.47 (150–903)

Abbreviations: nAMD, neovascular age macular degeneration; DME, diabetic macular edema; RVO, retinal vein occlusion with cystoid macular edema, Others (e.g. myopic choroidal neovascularization, polypoidal choroidal vasculopathy, punctate inner choroidopathy).

Table 3 Treatment in Pre-COVID and In-COVID Periods

Type of Injections	Bevacizumab (Avastin)	Aflibercept (Eylea)	Ranibizumab (Lucentis)	Total
Pre-COVID (Total Patients = 607)
Number of injections	475 (67.4%)	168 (23.8%)	62 (8.8%)	705
In-COVID (Total Patients = 394)
Number of injections	313 (59.8%)	160 (30.6%)	50 (9.6%)	523
Number of injections in Pre-COVID versus In-COVID				P-value>0.9